Other Non-Current Liabilities
Amgen Other Non-Current Liabilities decreased by 0.5% to $2.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.0%, from $2.21B to $2.37B. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 3.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.06B | $2.16B | $2.47B | $2.73B | $2.95B | $2.88B | $2.65B | $2.53B | $2.54B | $2.31B | $2.33B | $2.36B | $2.36B | $2.20B | $2.35B | $2.21B | $2.34B | $2.22B | $2.38B | $2.37B |
| QoQ Change | — | +5.1% | +14.1% | +10.8% | +7.9% | -2.5% | -7.8% | -4.5% | +0.2% | -9.1% | +0.9% | +1.3% | +0.3% | -6.9% | +6.8% | -5.9% | +5.7% | -4.8% | +7.0% | -0.5% |
| YoY Change | — | — | — | — | +43.5% | +33.1% | +7.5% | -7.3% | -14.0% | -19.8% | -12.3% | -6.9% | -6.8% | -4.6% | +1.0% | -6.2% | -1.1% | +1.1% | +1.2% | +7.0% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Amgen's other non-current liabilities?
- Amgen (AMGN) reported other non-current liabilities of $2.37B in Q1 2026.
- How has Amgen's other non-current liabilities changed year-over-year?
- Amgen's other non-current liabilities increased by 7.0% year-over-year, from $2.21B to $2.37B.
- What is the long-term trend for Amgen's other non-current liabilities?
- Over 5 years (2020 to 2025), Amgen's other non-current liabilities has grown at a 3.3% compound annual growth rate (CAGR), from $2.02B to $2.38B.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.